Background: To date, only a few real-world-setting studies evaluated apremilast effectiveness in psoriatic arthritis (PsA). The aims of this retrospective observational study are to report long-term Disease Activity Index for Psoriatic Arthritis (DAPSA) response of apremilast in PsA patients and to analyze the predictors of clinical response. Methods: All PsA consecutive patients treated with apremilast in fifteen Italian rheumatological referral centers were enrolled. Anamnestic data, treatment history, and PsA disease activity (DAPSA) at baseline, 6 months, and 12 months were recorded. The Mann–Whitney test and chi-squared tests assessed the differences between independent groups, whereas the Wilcoxon matched pairs signed-rank test assessed the differences between dependent samples. Logistic regressions verified if there were factors associated with achievement of DAPSA low disease activity or remission at 6 and 12 months. Results: DAPSA low disease activity or remission rates at 6 and 12 months were observed, respectively, in 42.7% (n = 125) and 54.9% (n = 161) patients. Baseline DAPSA was inversely associated with the odds of achieving low disease activity or remission at 6 months (odds ratio (OR) 0.841, 95% confidence interval (CI) 0.804–0.879; p < 0.01) and at 12 months (OR 0.911, 95% CI 0.883–0.939; p < 0.01). Conclusions: Almost half of the PsA patients receiving apremilast achieved DAPSA low disease activity or remission at 6 and 12 months. The only factor associated with achievement of low disease activity or remission at both 6 and 12 months was baseline DAPSA.

Predictors of DAPSA Response in Psoriatic Arthritis Patients Treated with Apremilast in a Retrospective Observational Multi-Centric Study (2023-02-07) / Becciolini, Andrea; Parisi, Simone; Del Medico, Patrizia; Farina, Antonella; Visalli, Elisa; Biagio Molica Colella, Aldo; Lumetti, Federica; Caccavale, Rosalba; Scolieri, Palma; Andracco, Romina; Girelli, Francesco; Bravi, Elena; Colina Alessandro Volpe, Matteo; Ianniello, Aurora; Chiara Ditto, Maria; Nucera, Valeria; Franchina, Veronica; Platè, Ilaria; Di Donato, Eleonora; Amato, Giorgio; Salvarani, Carlo; Bernardi, Simone; Lucchini, Gianluca; De Lucia, Francesco; Molica Colella, Francesco; Santilli, Daniele; Mansueto, Natalia; Ferrero, Giulio; Marchetta, Antonio; Arrigoni, Eugenio; Foti, Rosario; Sandri, Gilda; Bruzzese, Vincenzo; Paroli, Marino; Fusaro, Enrico; Ariani, Alarico. - In: BIOMEDICINES. - ISSN 2227-9059. - 11:2(2023), pp. 1-9. [10.3390/biomedicines11020433]

Predictors of DAPSA Response in Psoriatic Arthritis Patients Treated with Apremilast in a Retrospective Observational Multi-Centric Study (2023-02-07)

Federica Lumetti;Carlo Salvarani;Gilda Sandri;
2023

Abstract

Background: To date, only a few real-world-setting studies evaluated apremilast effectiveness in psoriatic arthritis (PsA). The aims of this retrospective observational study are to report long-term Disease Activity Index for Psoriatic Arthritis (DAPSA) response of apremilast in PsA patients and to analyze the predictors of clinical response. Methods: All PsA consecutive patients treated with apremilast in fifteen Italian rheumatological referral centers were enrolled. Anamnestic data, treatment history, and PsA disease activity (DAPSA) at baseline, 6 months, and 12 months were recorded. The Mann–Whitney test and chi-squared tests assessed the differences between independent groups, whereas the Wilcoxon matched pairs signed-rank test assessed the differences between dependent samples. Logistic regressions verified if there were factors associated with achievement of DAPSA low disease activity or remission at 6 and 12 months. Results: DAPSA low disease activity or remission rates at 6 and 12 months were observed, respectively, in 42.7% (n = 125) and 54.9% (n = 161) patients. Baseline DAPSA was inversely associated with the odds of achieving low disease activity or remission at 6 months (odds ratio (OR) 0.841, 95% confidence interval (CI) 0.804–0.879; p < 0.01) and at 12 months (OR 0.911, 95% CI 0.883–0.939; p < 0.01). Conclusions: Almost half of the PsA patients receiving apremilast achieved DAPSA low disease activity or remission at 6 and 12 months. The only factor associated with achievement of low disease activity or remission at both 6 and 12 months was baseline DAPSA.
2023
7-feb-2023
11
2
1
9
Predictors of DAPSA Response in Psoriatic Arthritis Patients Treated with Apremilast in a Retrospective Observational Multi-Centric Study (2023-02-07) / Becciolini, Andrea; Parisi, Simone; Del Medico, Patrizia; Farina, Antonella; Visalli, Elisa; Biagio Molica Colella, Aldo; Lumetti, Federica; Caccavale, Rosalba; Scolieri, Palma; Andracco, Romina; Girelli, Francesco; Bravi, Elena; Colina Alessandro Volpe, Matteo; Ianniello, Aurora; Chiara Ditto, Maria; Nucera, Valeria; Franchina, Veronica; Platè, Ilaria; Di Donato, Eleonora; Amato, Giorgio; Salvarani, Carlo; Bernardi, Simone; Lucchini, Gianluca; De Lucia, Francesco; Molica Colella, Francesco; Santilli, Daniele; Mansueto, Natalia; Ferrero, Giulio; Marchetta, Antonio; Arrigoni, Eugenio; Foti, Rosario; Sandri, Gilda; Bruzzese, Vincenzo; Paroli, Marino; Fusaro, Enrico; Ariani, Alarico. - In: BIOMEDICINES. - ISSN 2227-9059. - 11:2(2023), pp. 1-9. [10.3390/biomedicines11020433]
Becciolini, Andrea; Parisi, Simone; Del Medico, Patrizia; Farina, Antonella; Visalli, Elisa; Biagio Molica Colella, Aldo; Lumetti, Federica; Caccavale, Rosalba; Scolieri, Palma; Andracco, Romina; Girelli, Francesco; Bravi, Elena; Colina Alessandro Volpe, Matteo; Ianniello, Aurora; Chiara Ditto, Maria; Nucera, Valeria; Franchina, Veronica; Platè, Ilaria; Di Donato, Eleonora; Amato, Giorgio; Salvarani, Carlo; Bernardi, Simone; Lucchini, Gianluca; De Lucia, Francesco; Molica Colella, Francesco; Santilli, Daniele; Mansueto, Natalia; Ferrero, Giulio; Marchetta, Antonio; Arrigoni, Eugenio; Foti, Rosario; Sandri, Gilda; Bruzzese, Vincenzo; Paroli, Marino; Fusaro, Enrico; Ariani, Alarico
File in questo prodotto:
File Dimensione Formato  
biomedicines-11-00433.pdf

Open access

Tipologia: Versione pubblicata dall'editore
Dimensione 1.01 MB
Formato Adobe PDF
1.01 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1296690
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 1
social impact